PMID- 31608225
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231104
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 9
DP  - 2019
TI  - The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With 
      Increased Survival in CMV Positive Patients Undergoing Haploidentical 
      Hematopoietic Stem Cell Transplantation.
PG  - 888
LID - 10.3389/fonc.2019.00888 [doi]
LID - 888
AB  - Specific major histocompatibility (MHC) class I alleles dominate anti-CMV 
      responses in a hierarchal manner. These CMV immunodominant (IMD) alleles are 
      associated with a higher magnitude and frequency of cytotoxic lymphocyte 
      responses as compared to other human leukocyte antigen (HLA) alleles. CMV 
      reactivation has been associated with an increased incidence of graft-vs.-host 
      disease and non-relapse mortality, as well as protection from relapse in 
      HLA-matched HSCT settings. Less is known about the impact of CMV reactivation on 
      these major outcomes after haploidentical (HI) HSCT, an increasingly applied 
      therapeutic option. In HI HSCT, the efficiency of the immune response is 
      decreased due to the immune suppression required to cross the MHC barrier as well 
      as MHC mismatch between presenting and responding cells. We hypothesized that the 
      presence of a CMV IMD allele would increase the efficiency of CMV responses after 
      HI HSCT potentially impacting CMV-related outcomes. In this retrospective, 
      multivariable review of 216 HI HSCT patients, we found that CMV+ recipients 
      possessing at least 1 of 5 identified CMV IMD alleles had a lower hazard of death 
      (HR = 0.40, p = 0.003) compared to CMV+ recipients not possessing a CMV IMD 
      allele, and an overall survival rate similar to their CMV- counterparts. The 
      analysis delineated subgroups within the CMV+ population at greater risk for 
      death due to CMV reactivation.
CI  - Copyright (c) 2019 Grosso, Leiby, Carabasi, Filicko-O'Hara, Gaballa, O'Hara, Wagner 
      and Flomenberg.
FAU - Grosso, Dolores
AU  - Grosso D
AD  - Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas 
      Jefferson University, Philadelphia, PA, United States.
FAU - Leiby, Benjamin
AU  - Leiby B
AD  - Pharmacology and Experimental Therapeutics, The Sidney Kimmel Cancer Center at 
      Thomas Jefferson University, Philadelphia, PA, United States.
FAU - Carabasi, Matthew
AU  - Carabasi M
AD  - Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas 
      Jefferson University, Philadelphia, PA, United States.
FAU - Filicko-O'Hara, Joanne
AU  - Filicko-O'Hara J
AD  - Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas 
      Jefferson University, Philadelphia, PA, United States.
FAU - Gaballa, Sameh
AU  - Gaballa S
AD  - Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas 
      Jefferson University, Philadelphia, PA, United States.
FAU - O'Hara, William
AU  - O'Hara W
AD  - Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas 
      Jefferson University, Philadelphia, PA, United States.
FAU - Wagner, John L
AU  - Wagner JL
AD  - Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas 
      Jefferson University, Philadelphia, PA, United States.
FAU - Flomenberg, Neal
AU  - Flomenberg N
AD  - Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas 
      Jefferson University, Philadelphia, PA, United States.
LA  - eng
PT  - Journal Article
DEP - 20190917
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC6758597
OTO - NOTNLM
OT  - CMV
OT  - DNA terminase complex inhibitor
OT  - graft versus host disease
OT  - haploidentical
OT  - immunodominant allele
OT  - transplant outcomes
EDAT- 2019/10/15 06:00
MHDA- 2019/10/15 06:01
PMCR- 2019/01/01
CRDT- 2019/10/15 06:00
PHST- 2019/07/24 00:00 [received]
PHST- 2019/08/27 00:00 [accepted]
PHST- 2019/10/15 06:00 [entrez]
PHST- 2019/10/15 06:00 [pubmed]
PHST- 2019/10/15 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2019.00888 [doi]
PST - epublish
SO  - Front Oncol. 2019 Sep 17;9:888. doi: 10.3389/fonc.2019.00888. eCollection 2019.